Clinical Trials Browser

Completed × Neuroendocrine Tumors × CNS × Clear all

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT04400474 2025-06-19

CABATEN

Phase 2 Completed

93 enrolled 17 charts

CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

NCT06211803 2024-01-18

JPETClinic

Completed

10 enrolled

CNSEndocrineNET

Brain Neoplasms, Neuroendocrine Tumors, Neurodegenerative Diseases

NCT00442533 2023-04-03

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Phase 2/3 Completed

200 enrolled

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Somatostatinoma, Neuroendocrine Tumors

NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

Phase 2 Completed

39 enrolled 9 charts

CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT03042416 2022-01-10

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

Phase 3 Completed

400 enrolled

CNSEndocrineNET

Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Congenital Hyperinsulinism

NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Phase 2 Completed

68 enrolled 8 charts

CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

NCT02441062 2020-12-21

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

Phase 2 Completed

122 enrolled 6 charts

CNSEndocrineNET

Carcinoid Tumor, Medulloblastoma, Neuroblastoma, Neuroendocrine Tumors

NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Phase 1/2 Completed

24 enrolled 8 charts

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT01135849 2015-11-17

B-Receptor Signaling in Cardiomyopathy

Completed

99 enrolled

BreastCNSClassical hematologyDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidMyeloidNETOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Amyloidosis, Anemia, Anus Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Renal Cell, Colonic Neoplasms, Endocrine Gland Neoplasms, Esophageal Neoplasms, Eye Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Hodgkin Disease, Leukemia, Lung Neoplasms, Lymphoma, Non-Hodgkin, Mesothelioma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neurologic Manifestations, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT00339131 2011-10-12

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

Phase 1 Completed

24 enrolled

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors